Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Khiron Life Sciences Corp. (V:KHRN)

Business Focus: Alternative Medicine

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: 100 King St.W.
Suite 1600, 1 First Canadian Place
Tel: 1-833-2758984
IR: See website
Key People
Chris Naprawa
Chairman of the Board
Alvaro Torres
Chief Executive Officer, Director
Joel Friedman
Chief Financial Officer
Franziska Katterbach
President, Khiron Europe
Tejinder Virk
President Khiron Europe
Business Overview
Khiron Life Sciences Corp, formerly Adent Capital Corp, is a Canada-based company engaged in alternative medicine sector. The Company is an integrated medical cannabis company with its core operations in Latin America. Khiron is active in the research area in medical cannabis industry. It develops and commercializes medical cannabis products mainly in Colombia.
Financial Overview
For the six months ended 30 June 2021, Khiron LifeSciences Corp revenues increased 58% to C$5.6M. Net lossdecreased 31% to C$10.3M. Revenues reflect Medical productssegment increase from C$26K to C$1.4M, Health servicessegment increase of 23% to C$4.2M. Lower net loss reflectsShare-based compensation decrease of 42% to C$2M (expense),Salaries decrease of 19% to C$4.9M (expense).
Employees: 260 as of Dec 31, 2020
Reporting Currency: Canadian Dollars
Enterprise value: $44.77M as of Jun 30, 2021
Annual revenue (TTM): $10.09M as of Jun 30, 2021
EBITDA (TTM): -$17.44M as of Jun 30, 2021
Net annual income (TTM): -$19.38M as of Jun 30, 2021
Free cash flow (TTM): -$22.45M as of Jun 30, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 179,117,068 as of Jul 12, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization